In-patient discharge rates for the irritable bowel syndrome - An analysis of national trends in the United States from 1997 to 2010

Alimentary Pharmacology and Therapeutics

Volumn 38, Issue 11-12, 2013, Pages 1338-1346

  Sethi, S ^a   Wadhwa, V ^a   LeClair, J ^a   Mikami, S ^a   Park, R ^a   Jones, M ^b   Sethi, N ^a   Brown, A ^a   Lembo, A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MACQUARIE UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; DATABASES, FACTUAL; FEMALE; HOSPITAL COSTS; HOSPITALIZATION; HUMANS; INCIDENCE; INFANT; IRRITABLE BOWEL SYNDROME; LENGTH OF STAY; MALE; MIDDLE AGED; PATIENT DISCHARGE; UNITED STATES; YOUNG ADULT;

EID: 84893690803     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12532     Document Type: Article

References (34)

1. Drossman DA, Corazziari E, Talley NJ, et al. , eds. Rome III: The Functional GI Disorders. 3rd ed. Degnon Associates: McLean, VA, 2006.
2. Mitchell CM, Drossman DA. Survey of the AGA membership relating to patients with functional gastrointestinal disorders. Gastroenterology 1987; 92: 1282-4.
3. Hungin AP, Chang L, Locke GR, Dennis EH, Barghout V. Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact. Aliment Pharmacol Ther 2005; 21: 1365-75.
4. Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. An evidence-based position statement on the management of irritable bowel syndrome. Am J Gastroenterol 2009; 104(Suppl. 1): S1- 35.
5. Ruigomez A, Wallander MA, Johansson S, Garcia Rodriguez LA. One-year follow-up of newly diagnosed irritable bowel syndrome patients. Aliment Pharmacol Ther 1999; 13: 1097-102.
6. Houghton LA. Sensory dysfunction and the irritable bowel syndrome. Baillieres Best Pract Res Clin Gastroenterol 1999; 13: 415-27.
7. Longstreth GF, Yao JF. Irritable bowel syndrome and surgery: a multivariable analysis. Gastroenterology 2004; 126: 1665-73.
8. Caudill R. Health reform: the new reality. J Post Anesth Nurs 1993; 8: 349-52.
9. Fullerton S. Functional digestive disorders (FDD) in the year 2000 - economic impact. Eur J Surg Suppl 1998; 582: 62-4.
10. Gralnek IM. Health care utilization and economic issues in irritable bowel syndrome. Eur J Surg Suppl 1998; 583: 73-6.
11. Talley NJ, Gabriel SE, Harmsen WS, Zinsmeister AR, Evans RW. Medical costs in community subjects with irritable bowel syndrome. Gastroenterology 1995; 109: 1736-41.
12. Bentkover JD, Field C, Greene EM, Plourde V, Casciano JP. The economic burden of irritable bowel syndrome in Canada. Can J Gastroenterol 1999; 13 (Suppl. A): 89A-96A.
13. Cash B, Sullivan S, Barghout V. Total costs of IBS: employer and managed care perspective. Am J Manag Care 2005; 11(1 Suppl.): S7-16.
14. Healthcare Cost and Utilization Project Online[Internet]. Rockville, MD: Agency for Healthcare Research and Quality. Available at: http://www. hcup-us.ahrq.gov/nisoverview.jsp. Accessed October 18, 2013.
15. Healthcare Cost and Utilization Project Online [Internet]. Rockville, MD: Agency for Healthcare Research and Quality. Available at: ahrq.gov. Accessed October 18, 2013.
16. Health Insurance Coverage: Early Release of Estimates from the National Health Interview Survey, 2011 [Internet]. Atlanta, GA: Center for Disease Control and Prevention. Available at: http://www.cdc.gov/nchs/data/nhis/ earlyrelease/insur201206.pdf. Accessed October 18, 2013.
17. Kim HS, Kim MS, Ji SW, Park H. The development of irritable bowel syndrome after Shigella infection: 3 year follow-up study. Korean J Gastroenterol 2006; 47: 300-5.
18. Ilnyckyj A, Balachandra B, Elliott L, Choudhri S, Duerksen DR. Posttraveler's diarrhea irritable bowel syndrome: a prospective study. Am J Gastroenterol 2003; 98: 596-9.
19. Ruigomez A, Garcia Rodriguez LA, Panes J. Risk of irritable bowel syndrome after an episode of bacterial gastroenteritis in general practice: influence of comorbidities. Clin Gastroenterol Hepatol 2007; 5: 465-9.
20. Soyturk M, Akpinar H, Gurler O, et al. Irritable bowel syndrome in persons who acquired trichinellosis. Am J Gastroenterol 2007; 102: 1064-9.
21. Piche T, Vanbiervliet G, Pipau FG, et al. Low risk of irritable bowel syndrome after Clostridium difficile infection. Can J Gastroenterol 2007; 21: 727-31.
22. Marshall JK, Thabane M, Borgaonkar MR, James C. Postinfectious irritable bowel syndrome after a food-borne outbreak of acute gastroenteritis attributed to a viral pathogen. Clin Gastroenterol Hepatol 2007; 5: 457-60.
23. Marshall JK, Thabane M, Garg AX, et al. Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery. Gastroenterology 2006; 131: 445-50.
24. Wang LH, Fang XC, Pan GZ. Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut 2004; 53: 1096-101.
25. Neal KR, Hebden J, Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. BMJ 1997; 314: 779-82.
26. Thabane M, Kottachchi DT, Marshall JK. Systematic review and metaanalysis: the incidence and prognosis of post-infectious irritable bowel syndrome. Aliment Pharmacol Ther 2007; 26: 535-44.
27. Aujesky D, Auble TE, Yealy DM, et al. Prospective comparison of three validated prediction rules for prognosis in community-acquired pneumonia. Am J Med 2005; 118: 384-92.
28. Buising KL, Thursky KA, Black JF, et al. A prospective comparison of severity scores for identifying patients with severe community acquired pneumonia: reconsidering what is meant by severe pneumonia. Thorax 2006; 61: 419-24.
29. Bauer TT, Ewig S, Marre R, Suttorp N, Welte T. CRB-65 predicts death from community-acquired pneumonia. J Intern Med 2006; 260: 93-101.
30. Rockall TA, Logan RF, Devlin HB, Northfield TC. Variation in outcome after acute upper gastrointestinal haemorrhage. The National Audit of Acute Upper Gastrointestinal Haemorrhage. Lancet 1995; 346: 346-50.
31. Rockall TA, Logan RF, Devlin HB, Northfield TC. Selection of patients for early discharge or outpatient care after acute upper gastrointestinal haemorrhage. National Audit of Acute Upper Gastrointestinal Haemorrhage. Lancet 1996; 347: 1138-40.
32. Blatchford O, Murray WR, Blatchford M. A risk score to predict need for treatment for upper-gastrointestinal haemorrhage. Lancet 2000; 356: 1318-21.
33. Chandra S, Hess EP, Agarwal D, et al. External validation of the Glasgow- Blatchford Bleeding Score and the Rockall Score in the US setting. Am J Emerg Med 2012; 30: 673-9.
34. Laursen SB, Hansen JM, Schaffalitzky de Muckadell OB. The Glasgow Blatchford score is the most accurate assessment of patients with upper gastrointestinal hemorrhage. Clin Gastroenterol Hepatol 2012; 10: 1130-5.